Immuneering Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

54.65M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	-	-	-
Dec 31, 2022	316.95K	-1.76M	-84.76%
Dec 31, 2021	2.08M	-231.57K	-10.02%
Dec 31, 2020	2.31M	391.83K	20.41%
Dec 31, 2019	1.92M	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	400.28B
Johnson & Johnson	88.82B
Merck & Co.	64.17B
AbbVie	56.33B
AstraZeneca	54.07B
Novartis AG	51.72B
Eli Lilly and Company	45.04B
Thermo Fisher Scientific	42.88B

Revenue Rankings

IMRX News

19 days ago - Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
6 weeks ago - Why Is Immuneering Stock Trading Higher On Tuesday? - Benzinga
2 months ago - Immuneering Launches Pancreatic Cancer Advisory Board - GlobeNewsWire
2 months ago - Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Benzinga
2 months ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma - GlobeNewsWire
3 months ago - Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference - GlobeNewsWire
3 months ago - Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
5 months ago - Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - GlobeNewsWire

More News